EEE

ELICERA THERAPEUTICS AB

No trades
See on Supercharts
Market capitalization
‪65.62 M‬SEK
−0.915SEK
‪−16.40 M‬SEK
0.00SEK
‪14.91 M‬
Beta (1Y)
0.19
Employees (FY)
2
Change (1Y)
0
Revenue / Employee (1Y)
0.00SEK
Net income / Employee (1Y)
‪−809.24 K‬SEK

About ELICERA THERAPEUTICS AB


CEO
Jamal El-Mosleh
Headquarters
Gothenburg
Founded
2014
ISIN
SE0015382080
FIGI
BBG01161YY50
Elicera Therapeutics AB operates as a clinical stage immuno-oncology company, which engages in the development of cell and gene therapies for immune-based cancer treatments. Its drug candidates are in the field of oncolytic viruses and in the field of cell therapies, in addition to a platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune enhancement of treatments in said fields. Its product pipeline includes ELC-100, ELC-201, ELC-301, and ELC-401. The company was founded by Jamal El-Mosleh, Di Yu, and Magnus Essand in 2014 and is headquartered in Gothenburg, Sweden.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ELIC is 1.805 SEK — it has decreased by −3.48% in the past 24 hours. Watch ELICERA THERAPEUTICS AB stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange ELICERA THERAPEUTICS AB stocks are traded under the ticker ELIC.
ELIC stock has fallen by −2.43% compared to the previous week, the month change is a 17.59% rise, over the last year ELICERA THERAPEUTICS AB has showed a −68.22% decrease.
ELIC reached its all-time high on Aug 3, 2021 with the price of 9.000 SEK, and its all-time low was 0.850 SEK and was reached on May 15, 2024. View more price dynamics on ELIC chart.
See other stocks reaching their highest and lowest prices.
ELIC stock is 6.86% volatile and has beta coefficient of 0.19. Track ELICERA THERAPEUTICS AB stock price on the chart and check out the list of the most volatile stocks — is ELICERA THERAPEUTICS AB there?
Today ELICERA THERAPEUTICS AB has the market capitalization of ‪65.62 M‬, it has increased by 15.84% over the last week.
Yes, you can track ELICERA THERAPEUTICS AB financials in yearly and quarterly reports right on TradingView.
ELIC net income for the last quarter is ‪−5.62 M‬ SEK, while the quarter before that showed ‪−5.37 M‬ SEK of net income which accounts for −4.71% change. Track more ELICERA THERAPEUTICS AB financial stats to get the full picture.
No, ELIC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has 2.00 employees. See our rating of the largest employees — is ELICERA THERAPEUTICS AB on this list?
Like other stocks, ELIC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ELICERA THERAPEUTICS AB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ELICERA THERAPEUTICS AB technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ELICERA THERAPEUTICS AB stock shows the sell signal. See more of ELICERA THERAPEUTICS AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.